WILSON KAREN J 4

What Happened
Karen J. Wilson, a director of Serina Therapeutics, reported two open-market purchases (code P). On 2026-05-21 she acquired 10,000 shares at a weighted-average price of $1.77 for $17,700, and on 2026-05-22 she acquired 10,000 shares at a weighted-average price of $1.93 for $19,300 — a total of 20,000 shares for $37,000. These were purchases (buying stock), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction dates and prices:
  • 2026-05-21: 10,000 shares, weighted-average $1.77 (total $17,700). Footnote F1: this reflects multiple trades between $1.76 and $1.79.
  • 2026-05-22: 10,000 shares, weighted-average $1.93 (total $19,300). Footnote F2: this reflects multiple trades between $1.90 and $1.95.
• Total purchased: 20,000 shares for $37,000. Transaction code: P (purchase).
• Shares owned after the transactions: not disclosed in the information provided in this summary/filing.
• Filing timeliness: Form 4 filed 2026-05-26 for trades on 5/21 and 5/22; filing appears timely (filed within the SEC’s two-business-day window given the May 25 holiday).
• Footnote notes: weighted-average prices reflect multiple executions; the reporting person will provide per-price breakdowns upon written SEC request.

Context
These were straightforward open-market purchases by a company director (not an option exercise, gift, or tax-related withholding). Purchases by insiders are frequently watched by retail investors as a potential signal of confidence, but they are not proof of future performance. No additional info (e.g., ownership totals or 10% status) was disclosed in the supplied filing details.